DRUG-DRUG INTERACTION (DDI) STUDY BETWEEN THE INVESTIGATIONAL NAE INHIBITOR PEVONEDISTAT (TAK-924) AND FLUCONAZOLE OR ITRACONAZOLE IN PATIENTS WITH ADVANCED SOLID TUMORS.

被引：0
|
作者：
Faessel, H. M. [1 ]
Harvey, R. D. [2 ]
Lockhart, A. C. [3 ]
Bauer, T. M. [4 ]
Wang, L. [1 ]
Sedarati, F. [1 ]
Santillana, S. [1 ]
Nemunaitis, J. J. [5 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA
[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[5] Mary Crowley Canc Res Ctr, Dallas, TX USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-084
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [21] A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey A.
    Pavlick, Anna
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 47 - 58
  • [22] Phase 1 dose escalation study of the investigational drug TAK-960, an oral polo-like kinase 1 (PLK1) inhibitor, in patients (pts) with advanced solid tumors
    Calvo, E.
    Papadopoulos, K. P.
    Sharma, S.
    Cubillo, A.
    Rasco, D.
    Shi, H.
    Faucette, S.
    Zhou, X.
    Kuida, K.
    Oliva, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S181 - S181
  • [23] Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
    Jennifer R. Diamond
    Benjamin Wu
    Neeraj Agarwal
    Daniel W. Bowles
    Elaine T. Lam
    Theresa L. Werner
    Erik Rasmussen
    Erick Gamelin
    Felipe Soto
    Greg Friberg
    Yu-Nien Sun
    Sunil Sharma
    Investigational New Drugs, 2015, 33 : 691 - 699
  • [24] Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors
    Diamond, Jennifer R.
    Wu, Benjamin
    Agarwal, Neeraj
    Bowles, Daniel W.
    Lam, Elaine T.
    Werner, Theresa L.
    Rasmussen, Erik
    Gamelin, Erick
    Soto, Felipe
    Friberg, Greg
    Sun, Yu-Nien
    Sharma, Sunil
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (03) : 691 - 699
  • [25] Cabazitaxel plus cisplatin coadministration and drug-interaction study in patients with advanced solid tumors
    Mita, Alain C.
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Lane, Alex R.
    Moseley, Jennifer L.
    Mahalingam, Devalingam
    Tan, Benjamin R.
    Dedieu, Jean-Francois
    Stash, Diane
    Zhi, Xin
    Mazuir, Florent
    Lockhart, Albert C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Phase 1 Pharmacokinetic and Drug-Interaction Study of Dasatinib in Patients With Advanced Solid Tumors
    Johnson, Faye M.
    Agrawal, Shruti
    Burris, Howard
    Rosen, Lee
    Dhillon, Navneet
    Hong, David
    Blackwood-Chirchir, Anne
    Luo, Feng R.
    Sy, Oumar
    Kaul, Sanjeev
    Chiappori, Alberto A.
    CANCER, 2010, 116 (06) : 1582 - 1591
  • [27] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Effect of the CYP3A Inhibitor Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Advanced Solid Tumors: A Prospective, Multicenter, Open-Label, Randomized, Two-Way Crossover Drug-Drug Interaction Study
    Venkatakrishnan, Karthik
    Rader, Michael
    Ramanathan, Ramesh K.
    Ramalingam, Suresh
    Chen, Eric
    Riordan, William
    Trepicchio, William
    Cooper, Michael
    Karol, Michael
    von Moltke, Lisa
    Neuwirth, Rachel
    Egorin, Merrill
    Chatta, Gurkamal
    CLINICAL THERAPEUTICS, 2009, 31 : 2444 - 2458
  • [29] A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
    Vincent A. de Weger
    Sanjay Goel
    Roger von Moos
    Jan H. M. Schellens
    Nicholas Mach
    Eugene Tan
    Suraj Anand
    Jeffrey W. Scott
    Ulrik Lassen
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 73 - 80
  • [30] Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential
    LoRusso, Patricia M.
    Piha-Paul, Sarina A.
    Mita, Monica
    Colevas, A. Dimitrios
    Malhi, Vikram
    Colburn, Dawn
    Yin, Ming
    Low, Jennifer A.
    Graham, Richard A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 193 - 202
12345